The (II)logic of iron reduction therapy for steatohepatitis

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|62|3|668-670

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.62, Iss.3, 2015-09, pp. : 668-670

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

IRON THERAPY FOR AGED PATIENTS

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 6, Iss. 8, 1958-08 ,pp. : 621-622

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II, randomised, double‐blind, placebo‐controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH‐agonist therapy

By  

BJU INTERNATIONAL, Vol. 1464-4096, Iss. 5, 2015-11 ,pp. : 744-752

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II, randomised, double‐blind, placebo‐controlled trial of methylphenidate for reduction of fatigue levels in patients with prostate cancer receiving LHRH‐agonist therapy

By  

BJU INTERNATIONAL, Vol. 116, Iss. 5, 2015-11 ,pp. : 744-752

John Wiley & Sons Inc

Access to resources Recommend Favorite

COBALT‐IRON THERAPY FOR IRON‐DEFICIENCY ANEMIA

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 13, Iss. 5, 1965-05 ,pp. : 425-428

John Wiley & Sons Inc

Access to resources Recommend Favorite

Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?

By  

HEPATOLOGY, Vol. 54, Iss. 4, 2011-10 ,pp. : 1118-1120

John Wiley & Sons Inc

Access to resources Recommend Favorite